New peptide drug PQ203 enters human trials for Hard-to-Treat cancers

NCT ID NCT07190469

Recruiting now Disease control Sponsor: ProteinQure Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug called PQ203 in about 80 adults with advanced solid tumors, including triple-negative breast cancer, that have not responded to standard treatments. The drug is given as a weekly intravenous infusion. The main goals are to check safety and find the right dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PQ203 (a peptide drug-conjugate given by intravenous infusion once weekly)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors, especially triple-negative breast cancer.
What could go wrong: This is an early Phase 1 trial with only 80 participants, focused on safety and dosing. It is too soon to know if PQ203 will be effective, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS CANCER TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Show contact details

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 0C6, Canada

Contact Email: •••••@•••••
START Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.